XRAY

DENTSPLY SIRONA Inc. - Q1 2026 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. DENTSPLY SIRONA Inc. is the world's largest diversified manufacturer of professional dental products and technologies, operating through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company operates globally with significant exposure to the Americas, EMEA, and APAC regions.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales remained flat on a reported basis (+0.1%) but declined 6.7% on a constant currency basis. The decline was driven by lower volumes in Essential Dental Solutions (EDS) and Orthodontic and Implant Solutions (OIS), and the absence of Byte product sales in 2026.
• Profitability: The company reported an operating loss of $35 million compared to operating income of $63 million in the prior year. This was primarily due to a $67 million charge for restructuring and other costs (vs. $9 million in Q1 2025) and a 450 basis point compression in gross margin.
• Restructuring: A new restructuring plan ("2026 Plan") was approved in February 2026, resulting in $60 million in charges to date, primarily for severance. The plan targets $120 million in annualized cost savings.
• Dividends: The Board eliminated the quarterly dividend starting with the quarter ended March 31, 2026.
• Cash Flow: Operating cash flow improved significantly to $40 million, driven by reductions in accounts receivable and prepaid expenses, despite a net decrease in cash and equivalents of $136 million due to financing activities and investing outflows.

Guidance, Outlook, and Risks

• Outlook: Management expects global economic headwinds, including trade policy uncertainties and inflation, to weigh on growth for the remainder of 2026. Capital expenditures for the full year 2026 are estimated between $125 million and $150 million.
• R&D Investment: The company expects R&D investment to be at least 5% of annual net sales in 2026, focusing on the DS Core digital platform.
• Liquidity: The company maintains $684 million in available borrowings under credit facilities and believes it has sufficient liquidity for the next 12 months. No share repurchases were made in Q1 2026, with $1.2 billion of authorization remaining.
• Legal Contingencies: Significant ongoing litigation includes securities class actions regarding revenue recognition (2021-2022) and the Byte acquisition (2022-2024), as well as derivative suits against directors and officers. The company has accrued liabilities with offsetting insurance receivables for certain matters but cannot estimate potential losses for others.
• Geopolitical Risks: Operations in Israel, Russia, and Ukraine face risks from geopolitical conflicts. While operations in Israel remain open, cash repatriation from Russia is restricted due to currency controls and banking sanctions.

Investor Verification Checklist

• Restructuring Execution: Verify the timeline and cash impact of the $60-$65 million total expected charges under the 2026 Plan and the realization of the targeted $120 million in annualized savings.
• Byte Product Impact: Assess the long-term revenue gap left by the absence of Byte aligner sales and the strategy to replace this volume.
• Margin Recovery: Monitor gross margin trends to determine if the 48.5% margin is a new baseline or if recovery to prior levels (53%+) is achievable as tariff costs and volume mix stabilize.
• Litigation Exposure: Review the status of the consolidated securities litigation and derivative suits, specifically regarding the potential for settlements or adverse judgments that could exceed current accruals.
• Dividend Policy: Confirm if the elimination of the dividend is a permanent strategic shift to preserve cash for debt reduction and R&D or a temporary measure.